Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
about
Preparation of 5'-O-(1-Thiotriphosphate)-modified oligonucleotides using polymerase-endonuclease amplification reaction (PEAR)Follicular lymphoma: 2012 update on diagnosis and managementFollicular lymphoma: 2011 update on diagnosis and managementFollicular lymphoma: 2014 update on diagnosis and managementTreatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Rituximab in indolent lymphomas.Toll-like receptor agonists in cancer therapy.R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Toll-like receptor agonists: are they good adjuvants?The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Rituximab resistance.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanismTLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyHigh efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpGImmunomodulating antibodies and drugs for the treatment of hematological malignancies.Toll-like receptor modulators: a patent review (2006-2010).Combination strategies to enhance antitumor ADCC.Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.Toll-like receptors in the pathogenesis of human B cell malignancies.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Follicular lymphoma: 2015 update on diagnosis and management.A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.Immunotherapy for B-cell lymphoma: current status and prospective advancesTLR Agonists as Adjuvants for Cancer Vaccines.Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.Follicular lymphoma: 2018 update on diagnosis and management.NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity.The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.
P2860
Q21559611-35483C75-02EC-43D0-B9FC-2A7E3FF46889Q22252956-FEC2DB23-D341-472A-B49B-1CFA2CDA7AD6Q26851450-DAEE2E4D-FDE6-40E6-97FE-DF302A947C12Q27021850-52581AB5-5DAD-433B-910D-23F6716F4B1AQ27693252-8426DBB0-F07E-49B8-A2F9-5422EB9DF3D5Q33413438-A5A39AA9-EC40-4BB6-8B34-BA43323E45AEQ33690978-A2EE4A5C-5B24-4469-8E0E-BE27DAA0BE1FQ33764062-CD319A19-9886-4BED-BD47-161D36142126Q33918509-1A91A3D5-B187-42ED-AD2C-CF642B0D4A5DQ33934326-62E7503E-1F2B-498E-9F3C-26DF03495B90Q34056568-157C6B03-080F-4B80-9D68-634A8DD06C41Q34067537-E2F9DC72-3BA4-43A2-9617-4D676BC22C0DQ34310845-2CD303F7-2FB1-45F5-ADFA-BA8F994FAED6Q35018021-955D4F7C-4047-47BD-B16B-27E3C364A103Q35041270-6454CA20-7F30-47C8-A3BC-15A56D0C7C14Q35204579-2D176847-CF35-4C52-8371-2FA021274217Q35510560-D71D1F37-31F7-4F73-8A36-40D240F72D48Q36194849-C6858758-F27F-4090-BAC5-22F45606AFF6Q36608597-51712E67-D14B-45F4-BE49-FBC1D57970EFQ36625824-08E518BA-A92F-41A6-8209-516347EC3597Q37832694-65AD4EA0-4980-4576-903F-336EED160F4FQ37853197-8179036F-74FC-4758-AB83-FED4B97697F2Q38014085-A12FA867-FD06-478D-85AF-522E3CFC9AA1Q38174058-A892A3CA-9BA5-42E0-8581-7BE79AE7F59BQ38238963-36FDBAD5-4165-4947-9B8B-0C5662FBF88CQ38577849-16D932A4-6AEE-428A-8387-C0AEA407D5B4Q38797466-3BB01DCE-CDBB-4DB1-B18C-B011C71AAAA6Q39377049-DE875AAE-D0E2-48DB-A50B-A9D55E00AC43Q40122693-67C4CB90-8F4F-4403-A613-A2FDCAC32AACQ41000160-C45FC2C2-D708-4D8B-9EA8-76ADFB7DCAFAQ41831989-06390279-0D3F-4C9F-8864-DC6CD371EAD8Q41997055-0A7596FC-FAE4-40BA-95B1-6EB3ADEAF04DQ42247829-EAA7DC5F-2C6C-4EC6-9955-D121FF42F0C1Q42372842-B2F7DBBB-910B-427E-9DCF-B4C3634C2D6EQ47122380-600484E4-6E7C-46A3-AC8D-62A824FC502AQ47135118-1CA936A8-6B6D-4469-8800-CA59D4C42080Q47219215-E752B513-67C6-45B7-9EDB-45DDFC39B519Q51543249-C6FD8363-DC52-464F-8847-2A4A59D2363CQ52649735-EDCF7CF8-1FAB-489F-A2B2-26D3795CB93BQ54385532-F2702B1F-D9A6-4314-A766-3157C2293518
P2860
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of a TLR-9 agon ...... efractory follicular lymphoma.
@en
Phase II study of a TLR-9 agonist
@nl
type
label
Phase II study of a TLR-9 agon ...... efractory follicular lymphoma.
@en
Phase II study of a TLR-9 agonist
@nl
prefLabel
Phase II study of a TLR-9 agon ...... efractory follicular lymphoma.
@en
Phase II study of a TLR-9 agonist
@nl
P2093
P2860
P1476
Phase II study of a TLR-9 agon ...... efractory follicular lymphoma.
@en
P2093
Arnold S Freedman
David C Fisher
Derick R Peterson
Diana Marquis
Donna Neuberg
Elizabeth Ronan
Jane Liesveld
Jeffery L Kutok
Jennifer L Kelly
Jonathan W Friedberg
P2860
P304
P356
10.1111/J.1365-2141.2009.07773.X
P407
P577
2009-06-10T00:00:00Z